Imaging diagnosis of metastatic breast cancer

Pesapane, Filippo; Downey, Kate; Rotili, Anna; Cassano, Enrico; Koh, Dow‐Mu

doi:10.1186/s13244-020-00885-4

Cited by 56 publications

(42 citation statements)

References 125 publications

(177 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were also suggested by a review by Pesapane et al ( 28 ) in breast cancer. Importantly, that review suggested that WMBRI could be more sensitive than PET/CT for visceral metastases ( 28 – 30 ) and small hepatic and brain metastases ( 28 , 31 , 32 ), but WBMRI could be associated with more false-positives that PET/CT for bone metastases because bone marrow edema caused by benign lesions can appear as metastases on the apparent diffusion coefficient (ADC) map ( 28 ). A review highlighted that modern PET/CT protocols have a better diagnostic value than MRI for the detection of PCa metastases but that MRI still has a role to play ( 33 ).…”

Section: Resultssupporting

confidence: 90%

“…Since the present meta-analyses only examined bone metastases, this edema from benign lesions might explain, at least in part, why WBMRI fared less well than PET/CT. Nevertheless, other studies in patients with breast cancer reported a similar diagnostic value of WBMRI compared with 19 F-FDG PET/CT for bone metastases ( 34 ), highlighting that the DWI maps must not be read alone but in combination with the morphological changes ( 28 ). Gutzeit et al ( 35 ) reported better performance of WBMRI compared with PET/CT for skeletal metastases in PCa and breast cancer, while the SKELETA trial ( 25 ) reported equivalent diagnostic value for bone metastases from PCa.…”

Section: Resultsmentioning

confidence: 93%

See 1 more Smart Citation

Whole-Body MRI vs. PET/CT for the Detection of Bone Metastases in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis

Zhan

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Purpose: A recent meta-analysis in patients with non-small cell lung cancer showed no difference between whole-body magnetic resonance imaging (WBMRI) and positron emission tomography/computed tomography (PET/CT), but no such study is available for prostate cancer (PCa). This study aimed to compare WBMRI and PET/CT for bone metastasis detection in patients with PCa.Materials and Methods: PubMed, Embase, and the Cochrane library were searched for papers published up to April 2020. The population was the patients with untreated prostate cancer diagnosed by WBMRI or PET/CT. The outcomes were the true positive and negative and false positive and negative rates for WBMRI and PET/CT. The summarized sensitivity, specificity, positive likelihood ratios (PLR), negative likelihood ratios (NLR), and diagnostic odds ratios (DOR) were calculated with their 95% confidence intervals (CIs).Results: Four prospective and one retrospective study are included (657 patients). Significant differences are observed between WBMRI and PET/CT for sensitivity (WBMRI/PET/CT: 0.896; 95% CI: 0.813–0.987; P = 0.025) and NLR (WBMRI/PET/CT: 2.38; 95% CI: 1.13–5.01; P = 0.023), but not for specificity (WBMRI/PET/CT: 0.939; 95% CI: 0.855–1.031; P = 0.184) and PLR (WBMRI/PET/CT: 0.42; 95% CI: 0.08–2.22; P = 0.305). WBMRI has a similar a DOR compared with PET/CT (WBMRI/PET/CT: 0.13; 95% CI: 0.02–1.11; P = 0.062). The summary area under the receiver operating characteristic curves for WBMRI is 0.88 (standard error: 0.032) and 0.98 (standard error: 0.013) for PET/CT for diagnosing bone metastases in PCa.Conclusion: PET/CT presents a higher sensitivity and NLR for the bone metastasis detection from PCa, whereas no differences are found for specificity and PLR, compared with WBMRI.

show abstract

Section: Resultssupporting

confidence: 90%

Section: Resultsmentioning

confidence: 93%

Whole-Body MRI vs. PET/CT for the Detection of Bone Metastases in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis

Zhan

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Additionally, these studies were conducted before targeted therapies-currently used to treat metastatic breast cancer and proven to significantly reduce breast-cancer-related mortality 8 -were widely available. By contrast, current imaging modalities are capable of detecting small metastatic lesions in lymph nodes, 159 and every year, new targeted therapies extend PFS in metastatic breast cancer patients. 160 The development over the past decade of non-invasive biomarker assays promises to enable the low-cost early detection of cancer.…”

Section: Can Earlier Detection Of Recurrence Improve Breast Cancer Oumentioning

confidence: 97%

The lingering mysteries of metastatic recurrence in breast cancer

2020

View full text Add to dashboard Cite

Despite being the hallmark of cancer that is responsible for the highest number of deaths, very little is known about the biology of metastasis. Metastatic disease typically manifests after a protracted period of undetectable disease following surgery or systemic therapy, owing to relapse or recurrence. In the case of breast cancer, metastatic relapse can occur months to decades after initial diagnosis and treatment. In this review, we provide an overview of the known key factors that influence metastatic recurrence, with the goal of highlighting the critical unanswered questions that still need to be addressed to make a difference in the mortality of breast cancer patients.

show abstract

“…In our case, coexistence of NTM infection and breast cancer lung metastasis as well as primary lung cancer had been suspected. Currently, 18 F-FDG positron emission tomography/computed tomography ( 18 F-FDG PET/CT) is considered as the best method for detecting lung metastases with higher sensitivity to conventional imaging [15]. However, studies on the differentiation between benign and malignant lesions using 18 F-FDG PET/CT have been inconclusive.…”

Section: Discussionmentioning

confidence: 99%

Mycobacterium szulgai Lung Disease or Breast Cancer Relapse—Case Report

Kempisty¹,

Augustynowicz–Kopeć²,

Opoka³

et al. 2020

Antibiotics

View full text Add to dashboard Cite

Cancers are one of the risk factors of non-tuberculous mycobacterial (NTM) lung disease. The majority of data in this group of patients concern infections caused by Mycobacterium avium—the most prevalent NTM species worldwide. In contrast, limited information can be found regarding the uncommon NTM such as Mycobacterium szulgai. We present the case of M. szulgai lung disease in a patient with a history of breast cancer. Coexistence of NTM lung disease and breast cancer lung metastasis as well as primary lung cancer was suspected. Finally, neoplastic disease was ruled out based on negative results of endobronchial biopsy and negative tumor markers for lung and breast cancer. M. szulgai lung disease was successfully treated with rifampicin, ethambutol and clarithromycin.

show abstract

Imaging diagnosis of metastatic breast cancer

Cited by 56 publications

References 125 publications

Whole-Body MRI vs. PET/CT for the Detection of Bone Metastases in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis

Whole-Body MRI vs. PET/CT for the Detection of Bone Metastases in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis

The lingering mysteries of metastatic recurrence in breast cancer

Mycobacterium szulgai Lung Disease or Breast Cancer Relapse—Case Report

Contact Info

Product

Resources

About